{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:07:05Z","timestamp":1789146425023,"version":"build-2803163510"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117237","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:07:02Z","timestamp":1786061222000},"page":"117237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Breaking the relapse barrier: innovative approaches to improve CAR T-cell efficacy by targeting leukemic stem cells (LSCs) and measurable residual disease (MRD) in acute myeloid leukemia"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-6834","authenticated-orcid":false,"given":"Ashik Anil","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4084-7359","authenticated-orcid":false,"given":"Ronak","family":"Raheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7354-3459","authenticated-orcid":false,"given":"Pranav Thomas","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117237_bb0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13148-023-01529-2","article-title":"Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"15","author":"Chen","year":"2023","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.intimp.2026.117237_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2026.117237_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13543784.2023.2179482","article-title":"Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets","volume":"32","author":"Morse","year":"2023","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1016\/j.intimp.2026.117237_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-024-00490-x","article-title":"Challenges and strategies associated with CAR-T cell therapy in blood malignancies","volume":"13","author":"Liu","year":"2024","journal-title":"Exp Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0030","doi-asserted-by":"crossref","first-page":"1890594","DOI":"10.3389\/fimmu.2026.1890594","article-title":"Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs","volume":"17","author":"Mathew","year":"2026","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13237-025-00618-2","article-title":"CAR T cells beyond cancer: Emerging applications in autoimmunity and infectious diseases","volume":"68","author":"Mathew","year":"2025","journal-title":"Nucleus"},{"key":"10.1016\/j.intimp.2026.117237_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12964-023-01282-2","article-title":"The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways","volume":"21","author":"Bakhtiyari","year":"2023","journal-title":"Cell Commun Signal."},{"key":"10.1016\/j.intimp.2026.117237_bb0045","first-page":"338","article-title":"The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia: The tandem CLL1\/CD33 CAR-T to treat AML","volume":"23","author":"Wang","year":"2024","journal-title":"Blood Transfus."},{"key":"10.1016\/j.intimp.2026.117237_bb0050","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.3390\/cells10112833","article-title":"A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia","volume":"10","author":"Bolandi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117237_bb0055","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.3390\/ijms25136837","article-title":"Hematopoietic Stem Cells and Their Niche in Bone Marrow","volume":"25","author":"Kwon","year":"2024","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0065","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/jbmr.4678","article-title":"Osteoblast Lineage Support of Hematopoiesis in Health and Disease","volume":"37","author":"Kim","year":"2020","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.devcel.2023.02.003","article-title":"Endothelial and Leptin Receptor+ cells promote the maintenance of stem cells and hematopoiesis in early postnatal murine bone marrow","volume":"58","author":"Kara","year":"2023","journal-title":"Dev Cell."},{"key":"10.1016\/j.intimp.2026.117237_bb0075","doi-asserted-by":"crossref","first-page":"2400154","DOI":"10.1002\/bies.202400154","article-title":"Hematopoietic stem cell metabolism within the bone marrow niche \u2013 insights and opportunities","volume":"47","author":"Kemna","year":"2025","journal-title":"BioEssays"},{"key":"10.1016\/j.intimp.2026.117237_bb0080","doi-asserted-by":"crossref","first-page":"1236545","DOI":"10.3389\/fcell.2023.1236545","article-title":"Type H vessels: functions in bone development and diseases","volume":"11","author":"Liu","year":"2023","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.intimp.2026.117237_bb0085","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/cells10040722","article-title":"CXCL12-Abundant Reticular (CAR) Cells Direct Megakaryocyte Protrusions across the Bone Marrow Sinusoid Wall","volume":"10","author":"Wagner","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117237_bb0090","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s12015-021-10308-6","article-title":"Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications","volume":"18","author":"Long","year":"2022","journal-title":"Stem Cell Rev Rep."},{"key":"10.1016\/j.intimp.2026.117237_bb0095","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41375-025-02566-x","article-title":"Immune checkpoints regulate acute myeloid leukemia stem cells","volume":"39","author":"Reinhardt","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0100","doi-asserted-by":"crossref","first-page":"6643948","DOI":"10.1155\/2021\/6643948","article-title":"C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study","volume":"2021","author":"Wang","year":"2021","journal-title":"BioMed Res Int."},{"key":"10.1016\/j.intimp.2026.117237_bb0105","doi-asserted-by":"crossref","unstructured":"Khattab S, El Sorady M, El-Ghandour A, Visani G, Piccaluga PP: Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche. Explor Target Anti-Tumor Ther. 2024, 5:1027\u201355. 10.37349\/etat.2024.00262.","DOI":"10.37349\/etat.2024.00262"},{"key":"10.1016\/j.intimp.2026.117237_bb0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.leukres.2017.09.014","article-title":"Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo","volume":"62","author":"Bouvy","year":"2017","journal-title":"Leuk Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","article-title":"Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin Exp Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0125","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-025-58370-9","article-title":"Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance","volume":"16","author":"Takao","year":"2025","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2026.117237_bb0130","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.3390\/cancers16233974","article-title":"Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia","volume":"16","author":"Naji","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117237_bb0135","doi-asserted-by":"crossref","unstructured":"Erdem A, Morganti C, Totani H, Van Gastel N, Ito K: Intrinsic and niche-dependent metabolic regulation of haematopoietic stem cells and implications for leukaemogenesis. Nat Cell Biol. Published Online First: 11 February 2026. https:\/\/doi.org\/10.1038\/s41556-026-01872-5.","DOI":"10.1038\/s41556-026-01872-5"},{"key":"10.1016\/j.intimp.2026.117237_bb0140","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/molecules28010116","article-title":"Drug Resistance: The Role of Exosomal miRNA in the Microenvironment of Hematopoietic Tumors","volume":"28","author":"Cariello","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2026.117237_bb0145","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.3390\/ijms25084430","article-title":"Transforming the Niche: The Emerging Role of Extracellular Vesicles in Acute Myeloid Leukaemia Progression","volume":"25","author":"Mendes","year":"2024","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12885-024-11898-3","article-title":"TIM-3\/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1","volume":"24","author":"Shapourian","year":"2024","journal-title":"BMC Cancer."},{"key":"10.1016\/j.intimp.2026.117237_bb0155","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0160","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/cancers16061091","article-title":"Venetoclax Resistance in Acute Myeloid Leukemia","volume":"16","author":"Garciaz","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117237_bb0165","doi-asserted-by":"crossref","unstructured":"Brunner AM, Esteve J, Porkka K, et al.: Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024, 99:. 10.1002\/ajh.27161.","DOI":"10.1002\/ajh.27161"},{"key":"10.1016\/j.intimp.2026.117237_bb0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117237_bb0175","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"Van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117237_bb0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117237_bb0185","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0190","doi-asserted-by":"crossref","unstructured":"Ngai LL, Reuvekamp T, Hanekamp D, et al.: Different features of acute myeloid leukemia stem cell quantification in intensively treated patients. Haematologica. Published Online First: 30 April 2025. https:\/\/doi.org\/10.3324\/haematol.2024.287090.","DOI":"10.3324\/haematol.2024.287090"},{"key":"10.1016\/j.intimp.2026.117237_bb0195","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38\u2212 leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-024-01078-8","article-title":"Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study","volume":"14","author":"Hirsch","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2026.117237_bb0205","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0210","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022697","article-title":"Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation","volume":"144","author":"Wienecke","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0215","doi-asserted-by":"crossref","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci Adv."},{"key":"10.1016\/j.intimp.2026.117237_bb0220","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","article-title":"Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML","volume":"5","author":"Tsai","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117237_bb0225","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0235","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0240","doi-asserted-by":"crossref","first-page":"1152457","DOI":"10.3389\/fimmu.2023.1152457","article-title":"Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"14","author":"Shahzad","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0245","doi-asserted-by":"crossref","first-page":"1414264","DOI":"10.3389\/fimmu.2024.1414264","article-title":"Advances in CAR-NK cell therapy for hematological malignancies","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0255","doi-asserted-by":"crossref","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0260","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc Natl Acad Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00262-023-03594-1","article-title":"Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype","volume":"73","author":"Towers","year":"2024","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.intimp.2026.117237_bb0270","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0275","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","article-title":"C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2026.117237_bb0280","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0285","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cancers13133214","article-title":"CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117237_bb0290","doi-asserted-by":"crossref","unstructured":"Mushtaq MU, DiPersio JF, Azzi J, et al.: A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT. Blood J. 2026, blood.2025031053. https:\/\/doi.org\/10.1182\/blood.2025031053.","DOI":"10.1182\/blood.2025031053"},{"key":"10.1016\/j.intimp.2026.117237_bb0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-026-06742-6","article-title":"Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation","volume":"105","author":"Zhao","year":"2026","journal-title":"Ann Hematol."},{"key":"10.1016\/j.intimp.2026.117237_bb0300","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bjh.70019","article-title":"CD123 -targeting immunotherapeutic approaches in acute myeloid leukaemia","volume":"207","author":"Dreyzin","year":"2025","journal-title":"Br J Haematol."},{"key":"10.1016\/j.intimp.2026.117237_bb0305","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/ijms26030965","article-title":"Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation","volume":"26","author":"Kitte","year":"2025","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0310","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2024-208684","article-title":"Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0315","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001229","article-title":"Modulating TNF\u03b1 activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia","volume":"8","author":"Ataca Atilla","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2026.117237_bb0325","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood-2025-2372","article-title":"CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial","volume":"146","author":"Doherty","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0330","doi-asserted-by":"crossref","first-page":"1491341","DOI":"10.3389\/fimmu.2024.1491341","article-title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0335","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.3390\/cancers17213415","article-title":"FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML","volume":"17","author":"Stancioaica","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117237_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107690","article-title":"Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study","volume":"152","author":"Al Malki","year":"2025","journal-title":"Leuk Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0345","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117237_bb0350","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0355","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1111\/cas.15042","article-title":"TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways","volume":"112","author":"Kikushige","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0360","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70155","article-title":"Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy","volume":"9","author":"Van Der Schans","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.intimp.2026.117237_bb0370","doi-asserted-by":"crossref","first-page":"1093750","DOI":"10.3389\/fimmu.2023.1093750","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0375","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2026.117237_bb0380","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0385","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0390","doi-asserted-by":"crossref","first-page":"1260470","DOI":"10.3389\/fimmu.2023.1260470","article-title":"Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development","volume":"14","author":"P\u00e9rez-Amill","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0395","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1016\/j.ymthe.2025.05.033","article-title":"Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity","volume":"33","author":"Thomas","year":"2025","journal-title":"Mol Ther."},{"key":"10.1016\/j.intimp.2026.117237_bb0400","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther - Oncolytics."},{"key":"10.1016\/j.intimp.2026.117237_bb0405","article-title":"Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy","volume":"29","author":"Inthanachai","year":"2026","journal-title":"Immuno-Oncol Technol."},{"key":"10.1016\/j.intimp.2026.117237_bb0410","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/cancers16132455","article-title":"Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia","volume":"16","author":"Stefa\u0144czyk","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117237_bb0415","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical Evaluation of B7-H3\u2013specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0420","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1097\/CM9.0000000000003099","article-title":"B7-H3 in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target","volume":"137","author":"Tan","year":"2024","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.intimp.2026.117237_bb0425","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41375-025-02580-z","article-title":"LILRB1-directed CAR-T cells for the treatment of hematological malignancies","volume":"39","author":"Marhelava","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100126","article-title":"A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia","volume":"2","author":"Aribi","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.intimp.2026.117237_bb0435","doi-asserted-by":"crossref","unstructured":"Deng H, Wang Q, Tong X, Cui Z, Yang Y, Xiang Y: Recent advances of CAR-T cells in acute myeloid leukemia. Ther Adv Hematol 2025, 16:20406207251326802. https:\/\/doi.org\/10.1177\/20406207251326802.","DOI":"10.1177\/20406207251326802"},{"key":"10.1016\/j.intimp.2026.117237_bb0440","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0445","doi-asserted-by":"crossref","first-page":"1085978","DOI":"10.3389\/fimmu.2022.1085978","article-title":"Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia","volume":"13","author":"Schorr","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0450","doi-asserted-by":"crossref","first-page":"1557644","DOI":"10.3389\/fimmu.2025.1557644","article-title":"Chan GC-F, Chan WK: Designs of NKG2D-based immunotherapeutics for cancer","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0455","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0460","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1182\/blood-2022-165339","article-title":"CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia","volume":"140","author":"P\u00e9rez-Amill","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0465","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41375-025-02705-4","article-title":"A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias","volume":"39","author":"P\u00e9rez-Amill","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0470","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1182\/blood-2022-166790","article-title":"Preclinical Development of a CAR-T Cell Approach Targeting the CD84 Antigen Associated to Pediatric Acute Myeloid Leukemia","volume":"140","author":"Pigazzi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0475","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13045-025-01764-5","article-title":"Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Zhang","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0480","doi-asserted-by":"crossref","unstructured":"Lee W-HS, Ye Z, Cheung AMS, et al.: Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Mol Cancer Ther. 2021, 20:1702\u201312. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0155.","DOI":"10.1158\/1535-7163.MCT-20-0155"},{"key":"10.1016\/j.intimp.2026.117237_bb0485","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0490","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther."},{"key":"10.1016\/j.intimp.2026.117237_bb0495","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective killing of candidate AML stem cells by antibody targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0500","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004222","article-title":"Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia","volume":"10","author":"Trad","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2026.117237_bb0505","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-023-43843-6","article-title":"TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2026.117237_bb0510","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41587-025-02648-2","article-title":"Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein","volume":"44","author":"George","year":"2026","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.intimp.2026.117237_bb0515","doi-asserted-by":"crossref","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","article-title":"Marinovi\u0107 S: A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv."},{"key":"10.1016\/j.intimp.2026.117237_bb0520","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/cancers16010042","article-title":"Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances","volume":"16","author":"Canichella","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117237_bb0525","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40164-025-00726-4","article-title":"Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting","volume":"14","author":"Oca\u00f1a-Cara","year":"2025","journal-title":"Exp Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.811144","article-title":"Tumor Microenvironment in Acute Myeloid Leukemia: Adjusting Niches","volume":"13","author":"Menter","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0535","doi-asserted-by":"crossref","first-page":"1321596","DOI":"10.3389\/fimmu.2023.1321596","article-title":"Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges","volume":"14","author":"Harrer","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0540","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0545","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cac2.12474","article-title":"Novel CD123\u00d7CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity","volume":"43","author":"Wang","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.intimp.2026.117237_bb0550","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1200\/JCO.2021.39.15_suppl.10000","article-title":"The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis","volume":"39","author":"Zhang","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100751","article-title":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"31","author":"Boucher","year":"2023","journal-title":"Mol Ther - Oncolytics."},{"key":"10.1016\/j.intimp.2026.117237_bb0560","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.intimp.2026.117237_bb0565","doi-asserted-by":"crossref","unstructured":"Fedorov VD, Themeli M, Sadelain M: PD-1\u2013 and CTLA-4\u2013Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses. Sci Transl Med. 2013, 5:. 10.1126\/scitranslmed.3006597.","DOI":"10.1126\/scitranslmed.3006597"},{"key":"10.1016\/j.intimp.2026.117237_bb0570","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/cancers17243892","article-title":"The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia","volume":"17","author":"Segura Tudela","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117237_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117388","article-title":"Optimization of anti-TIM3 chimeric antigen receptor with CD8\u03b1 spacer and TNFR-based costimulation for enhanced efficacy in AML therapy","volume":"179","author":"Pe","year":"2024","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.intimp.2026.117237_bb0580","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2023022293","article-title":"IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0585","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2024-194162","article-title":"CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia","volume":"144","author":"Geyer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0590","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther."},{"key":"10.1016\/j.intimp.2026.117237_bb0595","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.3390\/ijms22168706","article-title":"TGF-\u03b2\/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma","volume":"22","author":"Noh","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0600","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0605","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","article-title":"Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells","volume":"38","author":"Volta","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117237_bb0610","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","article-title":"Safety switches for adoptive cell therapy","volume":"74","author":"Sahillioglu","year":"2022","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0615","article-title":"Regulation of CAR transgene expression to design semiautonomous CAR-T","volume":"32","author":"G\u0142owacki","year":"2024","journal-title":"Mol Ther Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0620","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117237_bb0625","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.775128","article-title":"Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities","volume":"12","author":"Marchand","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0635","article-title":"Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0640","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.intimp.2026.117237_bb0645","article-title":"Hypoxia-inducible CAR expression: An answer to the on-target\/off-tumor dilemma?","volume":"2","author":"Prinzing","year":"2021","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0650","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40364-020-00238-9","article-title":"Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing","volume":"8","author":"Liao","year":"2020","journal-title":"Biomark Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0655","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-021-01133-y","article-title":"Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0660","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature13034","article-title":"Direct measurement of local oxygen concentration in the bone marrow of live animals","volume":"508","author":"Spencer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117237_bb0665","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ncb2730","article-title":"Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment","volume":"15","author":"Nombela-Arrieta","year":"2013","journal-title":"Nat Cell Biol."},{"key":"10.1016\/j.intimp.2026.117237_bb0670","doi-asserted-by":"crossref","first-page":"39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci Rep."},{"key":"10.1016\/j.intimp.2026.117237_bb0675","doi-asserted-by":"crossref","unstructured":"Gao Y, Li J, Zhang H, et al.: Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial. Nat Cancer. Published Online First: 27 February 2026. https:\/\/doi.org\/10.1038\/s43018-026-01124-3.","DOI":"10.1038\/s43018-026-01124-3"},{"key":"10.1016\/j.intimp.2026.117237_bb0680","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fimmu.2019.01262","article-title":"Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X","volume":"10","author":"Levy","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0685","doi-asserted-by":"crossref","first-page":"eadl5100","DOI":"10.1126\/scisignal.adl5100","article-title":"CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism","volume":"17","author":"Rondeau","year":"2024","journal-title":"Sci Signal."},{"key":"10.1016\/j.intimp.2026.117237_bb0690","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41467-025-67745-x","article-title":"CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting","volume":"17","author":"Itoh-Nakadai","year":"2026","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2026.117237_bb0695","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181471","article-title":"IL-7\u2013mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models","volume":"135","author":"Singh","year":"2025","journal-title":"J Clin Invest."},{"key":"10.1016\/j.intimp.2026.117237_bb0700","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.3390\/ijms22136888","article-title":"Therapeutic Targeting of the Leukaemia Microenvironment","volume":"22","author":"Kuek","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100723","article-title":"Generation of hypoxia-sensing chimeric antigen receptor T cells","volume":"2","author":"Kosti","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.intimp.2026.117237_bb0710","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012321","article-title":"Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.intimp.2026.117237_bb0715","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13016","article-title":"Niche heterogeneity in the bone marrow","volume":"1370","author":"Birbrair","year":"2016","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0720","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0725","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.intimp.2026.117237_bb0730","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci."},{"key":"10.1016\/j.intimp.2026.117237_bb0735","doi-asserted-by":"crossref","first-page":"2278229","DOI":"10.1080\/15384047.2023.2278229","article-title":"Higher PD-1\/Tim-3 expression on IFN-\u03b3+ T cells is associated with poor prognosis in patients with acute myeloid leukemia","volume":"24","author":"Huang","year":"2023","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.intimp.2026.117237_bb0740","first-page":"615","article-title":"Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am J Cancer Res."},{"key":"10.1016\/j.intimp.2026.117237_bb0745","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells","volume":"11","author":"You","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0750","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/cells13181596","article-title":"Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia","volume":"13","author":"Bartoszewska","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117237_bb0755","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-025-02327-3","article-title":"Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion","volume":"11","author":"Wu","year":"2026","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.intimp.2026.117237_bb0760","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0765","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/2643-3230.BCD-23-0258","article-title":"CD33\u2013CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells","volume":"6","author":"Jambon","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117237_bb0770","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0775","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0780","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117237_bb0785","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.intimp.2026.117237_bb0790","doi-asserted-by":"crossref","first-page":"1691743","DOI":"10.3389\/fimmu.2025.1691743","article-title":"From innate-like to innate: the next wave of off-the-shelf CAR immunotherapies","volume":"16","author":"Feng","year":"2026","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0795","doi-asserted-by":"crossref","first-page":"1759796","DOI":"10.3389\/fonc.2025.1759796","article-title":"Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application","volume":"15","author":"Ren","year":"2026","journal-title":"Front Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0800","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med."},{"key":"10.1016\/j.intimp.2026.117237_bb0805","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2026.117237_bb0810","doi-asserted-by":"crossref","first-page":"1653183","DOI":"10.3389\/fimmu.2025.1653183","article-title":"Innate iNKT cells: from biological insight to clinical impact","volume":"16","author":"Rotolo","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0815","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11033-025-11407-0","article-title":"Redefining cell therapy: CAR-engineered innate immune cells to conquer solid and hematologic malignancies","volume":"53","author":"Mathew","year":"2026","journal-title":"Mol Biol Rep."},{"key":"10.1016\/j.intimp.2026.117237_bb0820","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","article-title":"Engineered natural killer cells for cancer therapy","volume":"43","author":"Biederst\u00e4dt","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.intimp.2026.117237_bb0825","doi-asserted-by":"crossref","first-page":"1545270","DOI":"10.3389\/fimmu.2025.1545270","article-title":"SynNotch CAR-T cell, when synthetic biology and immunology meet again","volume":"16","author":"Shirzadian","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.intimp.2026.117237_bb0830","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","article-title":"Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117237_bb0835","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1021\/acsbiomaterials.4c01039","article-title":"Investigation of Folate-Functionalized Magnetic-Gold Nanoparticles Based Targeted Drug Delivery for Liver: In Vitro, In Vivo and Docking Studies","volume":"10","author":"Alnasraui","year":"2024","journal-title":"ACS Biomater Sci Eng."},{"key":"10.1016\/j.intimp.2026.117237_bb0840","article-title":"Investigation of dextran-coated magnetic nanoparticles encapsulated by medication and modified with folate for targeted drug delivery: Invitro and docking studies","volume":"321","author":"Hussein","year":"2024","journal-title":"Mater Chem Phys."},{"key":"10.1016\/j.intimp.2026.117237_bb0845","doi-asserted-by":"crossref","DOI":"10.4110\/in.2025.25.e43","article-title":"Cytokine Engineering in CAR-T Cell Therapy: Next-Generation Strategies","volume":"25","author":"Kim","year":"2025","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2026.117237_bb0850","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/biomedicines12030599","article-title":"Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions","volume":"12","author":"Moritz","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.117237_bb0855","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s43856-024-00700-x","article-title":"Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models","volume":"4","author":"Mocking","year":"2024","journal-title":"Commun Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:13:15Z","timestamp":1789143195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926010830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":171,"alternative-id":["S1567576926010830"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117237","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking the relapse barrier: innovative approaches to improve CAR T-cell efficacy by targeting leukemic stem cells (LSCs) and measurable residual disease (MRD) in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117237"}}